# Bristol-Myers Squibb Company Ce (CELG-RI)

> Source: Nexqual · https://nexqual.com/CELG-RI · data as of 2026-10-14 19:45 UTC · cite as "Nexqual, Bristol-Myers Squibb Company Ce (CELG-RI), nexqual.com/CELG-RI" · informational, not investment advice.

**Price:** USD 0.12 (+0.00% on the day) · last close of Oct 14, 2026; US market closed, not a live price. Prev close 0.12 · day 0.12–0.13 · 52w 0.12–0.13 · market cap null · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $49.2B, net income $9.28B (18.9% margin), free cash flow $11.4B (SEC filings).

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B | $49.2B |
| Gross profit | $36.4B | $36.0B | $34.3B | $34.3B | $34.3B | — |
| Net income | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B | $9.28B |
| EPS (diluted) | $3.12 | $2.95 | $3.86 | -$4.41 | $3.46 | — |
| Free cash flow | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B | $11.4B |
| Gross margin | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% | — |
| Net margin | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% | 18.9% |
| Revenue growth | +9.1% | -0.5% | -2.5% | +7.3% | -0.2% | — |
| Cash + short-term investments | $17.0B | $9.25B | $12.3B | $10.9B | $10.7B | — |
| Total debt | $44.4B | $39.0B | $39.5B | $49.4B | $44.8B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)


## Peers
TAOX (Tao Synergies Inc.) USD 3.63 -1.49% · PCRX (Pacira BioSciences, Inc.) USD 36.33 +0.06% · BREZR (Breeze Acquisition Corp. II) USD 0.26 -7.14% · KTTAW (Pasithea Therapeutics Corp. Warrant) USD 0 +0.00% · HBIS (HOME BISTRO INC) USD 0 +0.00%

## More
Full page: https://nexqual.com/CELG-RI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt